S Sanofi
French multinational pharmaceutical and healthcare company
Updates & Highlights
Healthcare Digital · 7 days ago
This Week's Top 5: Lidl, Sanofi, GSK, NVIDIA and New NHS CTO
Oncodaily · 8 days ago
Belén Garijo: Sanofi Delivers Strong Half-Year Performance
Yahoo Finance · 8 days ago
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Recent Openings
View all 9 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Parental Leave
Family-friendly policies
Competitive Salary
Market-rate compensation
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Sanofi?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentThis Week's Top 5: Lidl, Sanofi, GSK, NVIDIA and New NHS CTO
This Week's Top 5: Lidl, Sanofi, GSK, NVIDIA and New NHS CTO
Healthcare Digital · 7 days ago
Belén Garijo: Sanofi Delivers Strong Half-Year Performance
Belén Garijo: Sanofi Delivers Strong Half-Year Performance
Oncodaily · 8 days ago
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Yahoo Finance · 8 days ago
Spotlight On: Sanofi meets the new boss, same as the old boss
Spotlight On: Sanofi meets the new boss, same as the old boss
FirstWord Pharma · 8 days ago
Sanofi's New Leadership Faces Looming Patent Cliff
Sanofi's New Leadership Faces Looming Patent Cliff
Morningstar · 9 days ago
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
Endpoints News · 9 days ago
Sanofi’s New CEO Highlights Pipeline Prioritization
Sanofi’s New CEO Highlights Pipeline Prioritization
DCAT Value Chain Insights · 9 days ago
Why Sanofi Stock Is Falling Thursday - Sanofi (NASDAQ:SNY)
Why Sanofi Stock Is Falling Thursday - Sanofi (NASDAQ:SNY)
Benzinga · 9 days ago
Regeneron Addresses Melanoma Trial Failure, Sanofi Negotiations, M&A Strategy on Q2 Earnings Call
Regeneron Addresses Melanoma Trial Failure, Sanofi Negotiations, M&A Strategy on Q2 Earnings Call
Precision Medicine Online · 9 days ago
European Stocks Advance on Busy Earnings Day; Sanofi Slumps
European Stocks Advance on Busy Earnings Day; Sanofi Slumps
Bloomberg.com · 9 days ago
Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline
Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline
WSJ · 9 days ago
Press Release: Sanofi’s half-year financial report for 2026
Press Release: Sanofi’s half-year financial report for 2026
Yahoo Finance · 9 days ago
Sanofi lifts 2026 outlook as dupilumab tops €5bn
Sanofi lifts 2026 outlook as dupilumab tops €5bn
EMJ · 9 days ago
Sanofi Q2 Earnings Call Highlights
Sanofi Q2 Earnings Call Highlights
Yahoo Finance · 9 days ago
Earnings call transcript: Sanofi beats Q2 2026 estimates but stock falls premarket
Earnings call transcript: Sanofi beats Q2 2026 estimates but stock falls premarket
Investing.com · 9 days ago
Sanofi drops two more programmes in R&D clear-out
Sanofi drops two more programmes in R&D clear-out
pharmaphorum · 9 days ago
Sanofi axes two more inflammatory-disease drugs
Sanofi axes two more inflammatory-disease drugs
European Biotechnology Magazine · 9 days ago
Why is Sanofi stock sliding today?
Why is Sanofi stock sliding today?
Investing.com · 9 days ago
Nektar: Sanofi’s Exit Clears A Competitor But Raises The Bar In Atopic Dermatitis (NKTR)
Nektar: Sanofi’s Exit Clears A Competitor But Raises The Bar In Atopic Dermatitis (NKTR)
Seeking Alpha · 12 days ago
Sanofi (NASDAQ: SNY) ends amlitelimab in atopic dermatitis trials
Sanofi (NASDAQ: SNY) ends amlitelimab in atopic dermatitis trials
Stock Titan · 12 days ago